Tate & Lyle PLC
F:TLY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
Tate & Lyle PLC
F:TLY
|
UK |
|
Z
|
Zimmer Biomet Holdings Inc
DUS:ZIM
|
US |
|
Medexus Pharmaceuticals Inc
F:P731
|
CA |
Wall St Price Targets
TLY Price Targets Summary
Tate & Lyle PLC
According to Wall Street analysts, the average 1-year price target for TLY is 8.093 EUR with a low forecast of 6.549 EUR and a high forecast of 10.894 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is TLY's stock price target?
Price Target
8.093
EUR
According to Wall Street analysts, the average 1-year price target for TLY is 8.093 EUR with a low forecast of 6.549 EUR and a high forecast of 10.894 EUR.
What is the Revenue forecast for Tate & Lyle PLC?
Projected CAGR
6%
Over the last 13 years, the compound annual growth rate for Revenue has been -4%. The projected CAGR for the next 5 years is 6%.
What is the Operating Income forecast for Tate & Lyle PLC?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Operating Income has been -3%. The projected CAGR for the next 5 years is 9%.
What is the Net Income forecast for Tate & Lyle PLC?
Projected CAGR
15%
Over the last 13 years, the compound annual growth rate for Net Income has been -6%. The projected CAGR for the next 5 years is 15%.
